| Original language | English (US) |
|---|---|
| Pages (from-to) | 1641-1642 |
| Number of pages | 2 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 127 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2011 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Allergy and Clinical Immunology, Vol. 127, No. 6, 06.2011, p. 1641-1642.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines
AU - Spector, Sheldon
AU - Wallace, Dana
AU - Nicklas, Richard
AU - Portnoy, Jay
AU - Blessing-Moore, Joann
AU - Bernstein, David
AU - Cox, Linda
AU - Oppenheimer, John
AU - Lang, David
AU - Schuller, Diane
AU - Randolph, Christopher
AU - Tilles, Stephen
AU - Khan, David
N1 - Funding Information: Disclosure of potential conflict of interest: S. Spector has consultant arrangements and is a speaker for AstraZeneca; receives research support and is a speaker for Novartis; receives research support from GlaxoSmithKline, TKL Perrigo, Amgen, AstraZeneca, Schering-Plough, GlaxoSmithKline, Genentech/Novartis, Boehringer Ingelheim, KarmelSonix, Merck, Medpoint, and Sunovion ; has provided expert witness testimony in cases related to mold allergy; is on a committee for ACAAI; and is a speaker/moderator for the AAAAI. R. Nicklas is a committee chair for the ACAAI. J. Blessing-Moore is on the speakers’ bureau for AstraZeneca, Merck, Novartis, Genentech, and Alcon; receives research support from Merck, Genentech, and Novartis ; is on the editorial board for the Task Force for Allergy Parameters; and is on committees for the AAAAI, the ACAAI, the ATS, and the ACCP. L. Cox has consultant arrangements with Stallergenes, receives research support from Stallergenes, and is on the board of directors for the AAAAI and the ABAI Joint Task Force . D. Lang is a speaker for GlaxoSmithKline; has served as a speaker and/or consultant for Merck, AstraZeneca, Teva, Sanofi Aventis, Genentech, and Novartis; and receives research support from Genentech/Novartis . D. Wallace has provided legal consultation/expert witness testimony on skin conditions in workers’ compensation cases and is president of the ACAAI. J. Portnoy is on the board for ACAAI and receives honoraria from Merck, Phadia, and UCB India. J. Oppenheimer has consultant arrangements with AstraZeneca, GlaxoSmithKline, and Merck; receives research support from Novartis, Merck, and GlaxoSmithKline ; and has provided legal consultation/expert witness testimony in cases related to medical malpractice defense. D. Schuller is past president of the ACAAI and is secretary-treasurer of the PA Allergy Society. S. Tilles is on the speakers’ bureau for Alcon and ISTA; has consultant arrangements with Merck; receives research support from Alcon, Amgen, Amphastar, Astellas, Boehringer Ingelheim, Ception, Genentech, Icagen, Merck, Novartis, Sepracor, and Aventis ; is employed part time as executive director of Asthma, Inc; is a member of the ACAAI; and serves as associate editor for Annals of Allergy and Allergy Watch. D. Khan is a speaker for AstraZeneca, Merck, and Genentech; receives research support from the Vanberg Family Foundation and the Sellars Family Foundation ; is the Conjoint Board Review Chair for ACAAI; and is past president of TAAIS. M. Dykewicz has received travel support from Merck and is vice chair of the Rhinitis Sinusitis Committee for the ACAAI . The rest of the authors have declared that they have no conflict of interest.
PY - 2011/6
Y1 - 2011/6
UR - http://www.scopus.com/inward/record.url?scp=79957800951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957800951&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2011.01.071
DO - 10.1016/j.jaci.2011.01.071
M3 - Letter
C2 - 21496893
AN - SCOPUS:79957800951
SN - 0091-6749
VL - 127
SP - 1641
EP - 1642
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -